Indications:
- Healing of Erosive Esophagitis: Lanso D effectively heals all grades of erosive esophagitis (EE) for up to 8 weeks.
- Maintenance of Healed Erosive Esophagitis: It ensures sustained healing of EE and alleviates heartburn for up to 6 months.
- Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD): Lanso D provides relief from heartburn associated with symptomatic non-erosive GERD for a duration of 4 weeks.
Pharmacology:
- Lanso D, containing dexlansoprazole, a Proton Pump Inhibitor (PPI), effectively curbs gastric acid secretion by selectively inhibiting the (H+/K+)-ATPase in gastric parietal cells.
- This formulation, presented as Dual Delayed Release (DDR) capsules, ensures a two-phase plasma concentration-time profile, ensuring sustained acid suppression.
Dosage:
- Dexlansoprazole: Administer 30 mg once daily for maintaining healed erosive esophagitis and relieving heartburn.
- Dexlansoprazole MUPS (Multiple Unit Pellet System): One 30 mg tablet once daily for maintenance of healed erosive esophagitis and alleviation of heartburn.
Administration:
- Dexlansoprazole can be taken regardless of meals, either as a whole capsule or by sprinkling intact granules from the capsule onto a tablespoon, followed by immediate swallowing.
Interaction:
- Lanso D may interact with several medications such as Atazanavir, Warfarin, Tacrolimus, Clopidogrel, and Methotrexate.
Contraindications:
- It is contraindicated in individuals exhibiting hypersensitivity to any constituent of the formulation.
Side Effects:
- Common side effects include diarrhea, abdominal pain, nausea, vomiting, and flatulence.
Pregnancy & Lactation:
- Pregnancy Category B; caution is advised during pregnancy and lactation due to limited data.
Precautions & Warnings:
- Caution is warranted in patients with gastric malignancy, Clostridium difficile-associated diarrhea, bone fracture, hypomagnesemia, and those concurrently using Methotrexate.
Use in Special Populations:
- Pediatric Use: Lanso D’s safety and efficacy have not been established in children under 12 years of age.
- Geriatric Use: No dose adjustment is required for elderly patients.
- Renal Impairment: No dose modification is necessary for patients with renal impairment.
- Hepatic Impairment: Consider a maximum daily dose of Lanso D 30 mg for patients with moderate hepatic impairment.
Overdose Effects:
- No significant cases of Lanso D overdose have been reported. Multiple doses of Lanso D 120 mg and a single dose of Lanso D 300 mg did not result in severe adverse events or fatalities.
Therapeutic Class:
- Lanso D belongs to the class of medications known as Proton Pump Inhibitors (PPIs), which effectively suppress gastric acid secretion.
Storage Conditions:
- Store Lanso D below 30°C in a dry place, shielded from light, and ensure it remains inaccessible to children.
Reviews
There are no reviews yet.